United States Patent 4,393,871: Scope, Claims, and Patent Landscape
Introduction
United States Patent 4,393,871 (hereafter "the '871 patent") was granted on July 19, 1983, to Chemische Fabrik Budenheim, GmbH, for its contribution to the pharmaceutical and chemical patent landscape. The patent discloses a specific class of chemical compounds, primarily focusing on a novel synthesis method and the subsequent application of these compounds. This analysis delineates the patent's scope, dissecting its claims to elucidate the boundaries of protection, and contextualizes its position within the broader patent landscape relevant to pharmaceuticals and chemical synthesis.
Scope of the Patent and Core Claims
1. Overview of the '871 Patent Focus
The '871 patent primarily claims a class of chemical compounds, their preparation methods, and their utility. It pertains to substituted aryl compounds, with specific substituents and configurations, characterized by their chemical structure and substitution pattern. The patent situates itself within the domain of compounds with biological activity, potentially including medicinal applications such as anti-inflammatory or analgesic effects, though its primary claim scope centers on the synthesis and composition.
2. Main Claims Dissection
Claim 1:
Covers a chemical compound of a general formula, with specific substituent definitions that include various heteroatoms, alkyl groups, and aromatic rings. Claim 1 functions as the broadest claim, setting the foundation for the scope of protection.
Claim 2-10:
Depend on Claim 1, further narrowing the scope to specific substituents, stereoisomers, or particular derivatives. These claims typically specify particular substituent groups, stereochemistry, or reaction conditions that enhance patent robustness, offering narrower but enforceable rights against infringing compounds fitting those detailed descriptions.
Claim 11-20:
Focus on the process for synthesizing the compounds, providing operational patents on chemical reactions or specific steps, such as reaction conditions, starting materials, or catalysts. These claims bolster patent strength by covering the methods used to produce the claimed compounds.
Claim 21-25:
Address the pharmaceutical compositions containing the compounds, including dosage forms, excipients, and claimed therapeutic uses, thus framing the patent within a medicinal context and extending protection to formulations.
Patent Landscape Analysis
1. Related Patent Families and International Footprint
The '871 patent belongs to a family of patents covering similar compounds or synthesis methods in jurisdictions like Europe (EP), Japan (JP), and Canada (CA), aligning with patent harmonization strategies typical in pharmaceutical R&D. The family includes patents primarily granted or pending in jurisdictions with significant pharmaceutical manufacturing / licensing activities, indicating an intent to secure global patent protection.
2. Competitive Landscape
-
Chemical Structural Class: The compounds belong to a class of substituted aryl derivatives widely explored for therapeutic properties, such as NSAIDs, anti-inflammatory agents, or central nervous system drugs. Many compounds within similar structural classes have existing patents or are off-patent, emphasizing the importance of precise claims to carve niche protection.
-
Prior Art Influence: Prior art during the early 1980s (e.g., references to similar aryl compounds and synthesis techniques) necessitated broad initial claims, with subsequent narrow claims to ensure enforceability without encroaching upon existing patents.
-
Patent Litigation and Challenges: The '871 patent has historically faced challenges in scope interpretation, particularly regarding the breadth of the chemical structure claims. Subsequent patent litigations have tested the scope, with courts emphasizing the importance of clear claim boundaries, especially for chemical genus claims.
3. Validity and Patent Term Status
As a patent granted in 1983, the '871 patent likely expired around 2000-2001, considering the standard 20-year term from the earliest filing date, barring extensions or terminal disclaimers. Its expiration opens opportunities for generic manufacturers or biosimilars, but during its enforceable life, the patent provided robust protection enabling licensing and exclusive commercialization.
4. Influence on Subsequent Patents
The '871 patent has served as a foundational patent for subsequent innovations related to similar compounds or derivatives. It influenced patent filings that centered around chemical modifications, improved synthesis pathways, or expanded therapeutic indications, thus shaping the chemical patent landscape for at least two decades.
Implications for Business and R&D
- Licensing Potential: During its active years, the patent served as a
